NVCN - Neovasc Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6500
+0.0147 (+2.31%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.6353
Open0.6400
Bid0.64 x 1000
Ask0.66 x 800
Day's Range0.6399 - 0.6600
52 Week Range0.4300 - 31.0000
Volume652,872
Avg. Volume1,312,888
Market Cap18.133M
Beta (3Y Monthly)2.61
PE Ratio (TTM)N/A
EPS (TTM)-14.17
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.88
Trade prices are not sourced from all markets
  • CNW Groupyesterday

    Neovasc Announces Refiling of Interim Financial Statements and Management's Discussion and Analysis for the Period Ended September 30, 2018

    The A&R Interim Financials and A&R MD&A have been refiled as the Company did not accrue for the future payments to be made under the terms of collaboration and settlement agreement with the University of Pennsylvania as press released on August 3 , 2018. The impact of the adjustment is to accrue for $1,379,790 of additional future collaboration and settlement payments in the current period increasing the loss for the period and the accrued liabilities as at September 30, 2018 .

  • PR Newswire3 days ago

    Neovasc Celebrates 5-Year Anniversary of Tiara Patient as the Longest Surviving Transcatheter Mitral Valve Replacement in the World

    VANCOUVER, Feb. 21, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that a patient implanted with a Tiara™ transcatheter mitral valve replacement device (the "Tiara") has celebrated her fifth anniversary since undergoing the procedure.  The Company believes that this patient is the longest surviving transcatheter mitral valve replacement therapy recipient in the world. Dr. Cheung stated, "This patient had a long history of ischemic cardiomyopathy with multiple heart failure hospitalizations.  She was referred to our heart failure program at St. Paul's Hospital for heart transplant evaluation.  Discussion with our Heart Team included the choice of either going onto the heart transplant list or receiving a very new technology, the Tiara.  We discussed the potential risks and benefits with her as she would be only the second patient in the world to receive this device.  She made the decision to move forward and successfully received the Tiara.

  • CNW Group4 days ago

    Neovasc Provides Corporate Update

    VANCOUVER , Feb. 20, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve technologies and in the development of minimally invasive devices for the treatment of refractory angina, today provided a corporate and operational update. 67% of all the Debt Notes (as defined below) initially issued in the 2017 Financings, and 92% of the Debt Notes held by one Debt Note holder, have been converted into the Company's common shares ("Common Shares") (one Debt Note holder has converted US$21.9 million of the US$23.9 million principal amount of Debt Notes initially issued to that Debt Note holder and, to date, the other Debt Note holders, holding US$8.8 million have not converted any of the Debt Notes they hold, leaving a total of US$10.8 million principal amount of Debt Notes outstanding).

  • CNW Group13 days ago

    Pierangeli Clinic Initiates Program Providing Neovasc Reducer™ Procedure to Italian Patients with Refractory Angina

    VANCOUVER , Feb. 11, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the Pierangeli Clinic of Pescara, Italy , under the guidance of its head of cardiology, Dr. Stefano Guarracini , has initiated a program to provide its patients access to the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for the treatment of refractory angina. On February 4, 2019 , the Pierangeli Clinic  preformed their first Reducer implant. The Pierangeli Clinic is the first facility to perform the Reducer in the Abruzzo region of Italy .

  • CNW Group25 days ago

    Neovasc Announces Renewal of German NUB Status 1 Designation for Neovasc Reducer™ Procedure for Treatment of Refractory Angina

    VANCOUVER , Jan. 30, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the "Institut für das Entgeltsystem im Krankenhaus" ("InEk"), the German Institute for the Hospital Remuneration System, has awarded its Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for the treatment of refractory angina, NUB status 1 designation again for 2019. The NUB process opens the path for negotiations between hospitals and health insurances on the reimbursement of new medical treatments in the German system.  InEK, is responsible for prioritizing new therapies in Germany through the NUB process.

  • ACCESSWIRE25 days ago

    These 4 Healthcare Stocks Healthy With Potential Opportunities

    With headlines popping up left and right, news surrounding these innovative companies in the healthcare industry has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), OncoCyte Corp (NYSE American: OCX), Neovasc Inc (NVCN), Zynerba Pharmaceuticals Inc (ZYNE) represent four healthcare companies working tirelessly to champion treatment solutions for the betterment of humankind. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.

  • CNW Group26 days ago

    Neovasc Receives Approval to Proceed with Phase 2 of TIARA-II Study from Clinical Regulators in Germany and the UK

    "The Neovasc team is excited about the positive news from the governmental healthcare authorities in Germany and the UK, as well as from the independent ethics committees in both countries.  After their review of the submitted, detailed results of the first 20 Tiara implants, we received all required approvals to continue this TIARA-II clinical study into the second and final phase of full enrollment, without further restrictions," commented Fred Colen , Neovasc's President and Chief Executive Officer. Tiara is a self-expanding mitral bioprosthesis specifically designed to treat mitral valve regurgitation (MR) by replacing the diseased valve.

  • ACCESSWIRElast month

    4 Healthcare Stocks Making Moves On Wednesday (1/23/19)

    CORAL GABLES, FL / ACCESSWIRE / January 23, 2019 / The future of healthcare stocks, and the medical sector industry as a whole, is solely dependent on the ability of medical experts and healthcare professionals to work to provide the best quality of care for patients in the space. With the rise of global population, coupled with depletion of most common resources, consumer access to healthcare is crucial to securing the health and wellness of all living people, resulting in a need for companies in the space to meet these demands. As companies in the healthcare industry work to better understand the needs of their patients, the sector, in its entirety, may boast impressive opportunities for investors looking to the space.

  • ACCESSWIRElast month

    Neovasc, Litigation Information and Product Reviews

    NEW YORK, NY / ACCESSWIRE / January 23, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Neovasc Inc. (NVCN), a specialty medical device company that develops, manufactures, and markets cardiovascular devices. On Friday, NVCN shares closed at $.7511 per share and Tuesday morning saw the company shares trade as high as $1.10.

  • CNW Grouplast month

    Neovasc announces peer reviewed publication in JACC demonstrating objective evidence of improvement in perfusion after Reducer implantation

    Neovasc announces peer reviewed publication in JACC demonstrating objective evidence of improvement in perfusion after Reducer implantation

  • ACCESSWIRElast month

    4 Healthcare Stocks Looking to Set the Pace on Tuesday (1/22/19)

    With the rise of global population, coupled with depletion of most common resources, consumer access to healthcare is crucial to securing the health and wellness of all living people, resulting in a need for companies in the space to meet these demands. Premier Health Group (OTC:PHGRF) (CSE:PHGI), MediWound Ltd (MDWD), Neovasc Inc (NVCN), and Teladoc Health Inc (TDOC) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients. Premier Health Group (OTC:PHGRF) (CSE:PHGI) has enjoyed impressive gains over the last three weeks as the company has taken strides to make key investments in the cannabis industry, allowing for the integration of new approaches to treatment options for their patients.

  • CNW Grouplast month

    Neovasc Announces Dismissal of Claim brought by Edwards Lifesciences

    VANCOUVER , Jan. 22, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that, pursuant to a settlement reached with Edwards Lifesciences PVT, Inc. and Edwards Lifesciences ( Canada ) Inc. (collectively, "Edwards"), the patent infringement action that Edwards had previously commenced in the Federal Court of Canada against Neovasc, Boston Scientific and Livanova, will be dismissed on a no-costs basis. Its products include the Neovasc Reducer™ (the "Reducer"), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States , Canada and Europe .

  • CNW Grouplast month

    Neovasc Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

    VANCOUVER , Jan. 14, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX:NVCN) announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

  • CNW Group2 months ago

    Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency

    VANCOUVER , Jan. 3, 2019 /CNW/ - ("Neovasc" or the "Company") (NVCN)(NVCN.TO), announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum market value requirement set forth in Nasdaq Rules for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(2) requires companies to maintain a minimum market value of US $35 million and Listing Rule 5810(c)(3)(C) provides that a failure to meet the market value requirement exists if the deficiency continues for a period of 30 consecutive business days.

  • CNW Group2 months ago

    Neovasc Receives ISO 13485: 2016 Certification

    VANCOUVER , Dec. 21, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it has received ISO 13485:2016 certification, an internationally recognized quality standard specific to the medical device industry. "As we continue to ramp up sales of the Neovasc Reducer™ in Europe and continue to execute on other R&D and clinical research activities, this certification confirms that our quality management system continues to adhere to the stringent requirements for the consistent design, development, production and delivery of medical devices," commented Fred Colen , Neovasc's President and Chief Executive Officer.